With an estimated 9.4 million new cases globally, tuberculosis (TB) continues to be a major
public health concern. Eighty percent of all cases worldwide occur in 22 high-burden, mainly …

Pyrazinamide (PZA) is a unique antituberculosis (anti-TB) drug that plays a key role in
shortening TB therapy. PZA kills nonreplicating persisters that other TB drugs fail to kill …

WHO Global Strategy for Containment of Antimicrobial Resistance Page 1 WHO/CDS/CSR/DRS/2001.2
DISTR: GENERAL ORIGINAL: ENGLISH WHO Global Strategy for Containment of …

The cornerstone of tuberculosis management is a 6‐month course of isoniazid, rifampicin,
pyrazinamide and ethambutol. Compliance is crucial for curing tuberculosis. Adverse effects …

Practical Handbook of Microbiology, 4th edition provides basic, clear and concise
knowledge and practical information about working with microorganisms. Useful to anyone …

Drug resistance in tuberculosis (TB) is a particular problem because the lengthy therapy of
at least 6 months makes patient compliance very difficult, which frequently creates drug …

Antimicrobial resistance is one of the biggest challenges facing global public health.
Although antimicrobial drugs have saved many lives and eased the suffering of many …

Ethionamide (ETH) is a structural analog of the antituberculosis drug isoniazid (INH). Both of
these drugs target InhA, an enzyme involved in mycolic acid biosynthesis. INH requires …

Part of the reason for failing to bring about a more rapid reduction in tuberculosis incidence
worldwide is the lack of effective involvement of all practitioners—public and private—in the …

Mathematical models predict that the future of the multidrug-resistant (MDR) and extensively
drug-resistant (XDR) tuberculosis (TB) epidemic will depend to a large extent on the …